Summary & Overview
HCPCS G9836: Reason for Not Administering Trastuzumab
HCPCS Level II code G9836 denotes documentation of the reason trastuzumab was not administered, capturing clinical and non-clinical causes such as patient refusal, death, transfer, contraindication, or incomplete neoadjuvant therapy. This code matters nationally because accurate capture of non-administration reasons affects oncology treatment records, quality measurement, care coordination, and administrative workflows across payers and delivery settings. Proper use supports claims clarity and downstream quality reporting tied to HER2-positive breast cancer management.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of this code’s clinical context, where it is typically used (infusion centers and outpatient oncology clinics), common modifiers and implementation considerations, and where to look for related documentation and billing implications. The publication outlines benchmarking and policy considerations relevant to national payer practices, clinical documentation expectations, and operational workflows for oncology departments. Data not provided in the input for specific taxonomies, ICD-10 pairings, or related codes is noted as unavailable; the focus remains on the code’s purpose, settings of use, and implications for claims processing and quality tracking.
Billing Code Overview
HCPCS Level II code G9836 documents the reason for not administering trastuzumab, capturing circumstances such as patient decline, death, transfer, clinical contraindication or exclusion, or incomplete neoadjuvant therapy (chemotherapy or radiation). This code is used to indicate that planned or expected administration of the HER2-directed monoclonal antibody trastuzumab did not occur and records the clinical or administrative rationale.
-
Service type: Oncology medication administration/documentation of non-administration
-
Typical site of service: Infusion center or outpatient oncology clinic
Clinical & Coding Specifications
Clinical Context
A patient with HER2-positive breast cancer was scheduled to receive intravenous trastuzumab as part of adjuvant or neoadjuvant therapy in an oncology infusion center or hospital outpatient chemotherapy unit. Prior to drug preparation or administration, the clinician documents that trastuzumab will not be administered because the patient declined therapy, experienced intercurrent death, transferred care to another facility, developed a documented contraindication (for example, new significant cardiac dysfunction), exhibited incomplete neoadjuvant chemotherapy or radiation sequencing that precludes starting trastuzumab, or another clinical exclusion. The workflow includes: initial oncology consultation, ordering of trastuzumab, pre-infusion nursing assessment (vitals, chemo consent, review of labs and echocardiogram), documentation of the specific reason for non-administration in the medical record, and billing the service using G9836 to indicate the reason for not administering trastuzumab. Typical sites of service are outpatient oncology infusion centers, hospital outpatient departments, ambulatory surgery centers when oncology infusions are delivered there, or inpatient settings if care is transferred or the patient dies before administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the complexity of documentation or work to explain non-administration is unusually high (e.g., extensive counseling or complex care coordination). |